The dietary supplements of various embodiments comprise a water-soluble vitamin component, an oil-soluble vitamin component, magnesium or derivatives thereof, a primary polyphenolic compound, a secondary polyphenolic compound, and an omega-3-phospholipid complex. The methods include maintaining health, maintaining brain health and reducing the risk or rate of neurodegeneration or cognitive decline. Methods, including algorithms, for systematically determining a dietary supplement are also described.

The dietary supplements of various embodiments comprise a water-soluble vitamin component, an oil-soluble vitamin component, magnesium or derivatives thereof, a primary polyphenolic compound, a secondary polyphenolic compound, and an omega-3-phospholipid complex. The methods include maintaining health, maintaining brain health and reducing the risk or rate of neurodegeneration or cognitive decline. Methods, including algorithms, for systematically determining a dietary supplement are also described.

A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.

A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising administering to the individual a multi-nutrient composition a protein, creatine, vitamin D, calcium and an n-3 fatty acid.

Provided is a useful pharmaceutical composition that exhibits effects of improving sleep quality, relieving stress, and reducing fatigue feeling in a mammal (for example, a human) target by ingestion or administration of a composition containing at least one substance selected from the group consisting of citric acid and a salt thereof.

A novel binder is provided. The binder comprises a polyvinyl alcohol-based polymer having an average saponification value of 96.0 mol% or more.

The present invention provides a fermented honey product obtained by fermenting a honey-containing material having a honey concentration of more than 25% with Lactobacillus kunkeei.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

A method of increasing apparent total tract digestibility and retention of calcium and phosphorus in a pig is provided. The method includes administering to the pig an effective amount of a vitamin D composition comprising at least one vitamin D compound. Related compositions are also provided.